GSK’s MAGE-A3 ASCI applicant is currently becoming evaluated as an adjuvant treatment in resected NSCLC in the Phase III clinical research MAGRIT, the biggest lung cancer treatment study ever conducted. To meet the requirements to receive GSK’s MAGE A3 ASCI, patients will need to have MAGE-A3 expressing NSCLC tumors. MAGE-A3 is normally a tumor-specific antigen that is expressed in non-little cell lung tumor and a multitude of other cancers, but not in regular cells. Under terms of the contract, Abbott, in conjunction with GSK, will establish and commercialize a PCR test made to detect MAGE A3 for use on the Abbott m2000 automated instrument system. That is a thrilling collaboration with a leading company in cancer immunotherapy research, said Stafford O’Kelly, mind of Abbott’s molecular diagnostics business.Care and regular medical information can help avoid all these complications, which are associated with abortion. It really is a safe treatment, but a little negligence could cause serious complications.
AMA enters health IT partnerships The American Medical Association has made handles computer retailer Dell, and Ingenix, a subsidiary of UnitedHealth Group, to help physicians adopt and implement electronic health records , the Chicago Tribune reports.